RLMD Relmada Therapeutics, Inc.: רווח נקי למניה (EPS TTM)

Net losses and the risk of equity dilution drive a negative hypothesis, which is confirmed by the trend of the rolling annual EPS. The value of -0.93 captures the metric level amid competition with market behemoths and a potential funding shortfall. Meanwhile, high macro-resilience and stable demand for neuropreparations regardless of crises support the long-term potential of Relmada Therapeutics (RLMD).

Earnings per share (EPS TTM) determines the actual investor income allocated to a single security. This metric aggregates annual profit, excluding distortions caused by capital changes through share issuances or buybacks. Analyzing the EPS TTM history allows for an assessment of asset monetization efficiency. For Relmada Therapeutics (RLMD), this parameter reflects the financial stability of its virtual biotech model. Minimizing the carbon footprint and conducting laboratory audits optimize operating expenses, thereby impacting the bottom line.